Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Long-Term Deferred Tax: 2015-2024

Historic Long-Term Deferred Tax for Adma Biologics (ADMA) over the last 5 years, with Dec 2024 value amounting to $84.3 million.

  • Adma Biologics' Long-Term Deferred Tax was N/A to $74.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.4 million, marking a year-over-year change of. This contributed to the annual value of $84.3 million for FY2024, which is N/A change from last year.
  • Per Adma Biologics' latest filing, its Long-Term Deferred Tax stood at $84.3 million for FY2024, which was up 137.09% from $35.5 million recorded in FY2018.
  • In the past 5 years, Adma Biologics' Long-Term Deferred Tax ranged from a high of $84.3 million in FY2024 and a low of $84.3 million during FY2024.
  • Its 1-year average for Long-Term Deferred Tax is $84.3 million, with a median of $84.3 million in 2024.